AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8142829 — intervention group
Group type: COMPARATOR
Intervention: Neutral taping of the patella
Number of subjects: 14
Study 8142829 — intervention group
Group type: COMPARATOR
Intervention: Lateral taping of the patella
Number of subjects: 14
Study 2905110 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil (0.5 mg intravenously over 10 minutes)
Number of subjects: 4
Study 2905110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31811650 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice alert (BPA) linked to a Smartset
Number of subjects: 2697
Study 31811650 — intervention group
Group type: COMPARATOR
Intervention: Best practice alert (BPA) alone
Number of subjects: 2697
Study 30099857 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian active bright white light (BWL)
Number of subjects: 44
Study 30099857 — intervention group
Group type: COMPARATOR
Intervention: Circadian inactive dim white light (DWL)
Number of subjects: 44
Study 27063071 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag 400 μg
Number of subjects: 19
Study 27063071 — intervention group
Group type: COMPARATOR
Intervention: Warfarin 20 mg
Number of subjects: 19
Study 24284464 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 25
Study 24284464 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 25
Study 23644932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4203
Study 23644932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (10 mg) + Zeaxanthin (2 mg)
Number of subjects: 4203
Study 23644932 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (350 mg) + EPA (650 mg)
Number of subjects: 4203
Study 23644932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein + Zeaxanthin and DHA + EPA
Number of subjects: 4203
Study 23644932 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene elimination
Number of subjects: 4203
Study 20595224 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication strategies training group
Number of subjects: 51
Study 20595224 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication strategies training plus psychosocial exercise group
Number of subjects: 51
Study 20595224 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational lecture plus psychosocial exercise group
Number of subjects: 51
Study 18400776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antivenom
Number of subjects: 126
Study 18400776 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular antivenom
Number of subjects: 126
Study 15930213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg, followed by 5 mg/kg after 24 and 48 hours)
Number of subjects: 155
Study 15930213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 15930213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 155
Study 12540788 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-isosorbide mononitrate (ISMN; 10 mg)
Number of subjects: 23
Study 12540788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 12800045 — intervention group
Group type: EXPERIMENTAL
Intervention: mepivacaine
Number of subjects: 57
Study 12800045 — intervention group
Group type: COMPARATOR
Intervention: sodium chlorid
Number of subjects: 57
Study 8800885 — intervention group
Group type: EXPERIMENTAL
Intervention: Operations performed by consultant urologists
Number of subjects: 100
Study 8800885 — intervention group
Group type: COMPARATOR
Intervention: Operations performed by trainee urologists
Number of subjects: 100
Study 8800885 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who absorbed irrigant fluid
Number of subjects: 100
Study 8800885 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not absorb irrigant fluid
Number of subjects: 100
Study 8800885 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with significant irrigant fluid absorption (peak breath alcohol > 300 mg/L) operated by consultant
Number of subjects: 100
Study 8800885 — intervention group
Group type: COMPARATOR
Intervention: Patients with significant irrigant fluid absorption (peak breath alcohol > 300 mg/L) operated by trainee
Number of subjects: 100
Study 1815520 — intervention group
Group type: EXPERIMENTAL
Intervention: Prajmalium bitartrate tablet (Neo‐Gilurytmal)
Number of subjects: 20
Study 1815520 — intervention group
Group type: COMPARATOR
Intervention: Oral solution of prajmalium bitartrate
Number of subjects: 20
Study 6655704 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex therapy
Number of subjects: 0
Study 6655704 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital therapy
Number of subjects: 0
Study 6655704 — intervention group
Group type: COMPARATOR
Intervention: Both therapies
Number of subjects: 0
Study 28910538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 50 rpm
Number of subjects: 8
Study 28910538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 80 rpm
Number of subjects: 8
Study 28910538 — intervention group
Group type: COMPARATOR
Intervention: Both conditions (50 rpm and 80 rpm)
Number of subjects: 8
Study 26387037 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TA) - single dose of 20 mg/kg
Number of subjects: 186
Study 26387037 — intervention group
Group type: COMPARATOR
Intervention: Standard drains
Number of subjects: 186
Study 26387037 — intervention group
Group type: COMPARATOR
Intervention: Reinfusion drains
Number of subjects: 186
Study 24807327 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 376
Study 24807327 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone
Number of subjects: 376
Study 22624299 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange maize (O1, O2, O3)
Number of subjects: 189
Study 22624299 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange maize (O3)
Number of subjects: 189
Study 22624299 — intervention group
Group type: COMPARATOR
Intervention: White maize
Number of subjects: 189
Study 19697326 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm with health education, visual inspection of cervix (with 4% acetic acid-VIA), and clinical breast examination (CBE)
Number of subjects: 151538
Study 19697326 — intervention group
Group type: COMPARATOR
Intervention: Control arm with only health education
Number of subjects: 151538
Study 18580364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-back condition with backpack loaded at 10% BW
Number of subjects: 10
Study 18580364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-back condition with backpack loaded at 20% BW
Number of subjects: 10
Study 18580364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-back condition with backpack loaded at 30% BW
Number of subjects: 10
Study 18580364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-back condition with backpack over one shoulder
Number of subjects: 10
Study 18580364 — intervention group
Group type: COMPARATOR
Intervention: Low-back condition
Number of subjects: 10
Study 16136031 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 13842
Study 16136031 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology
Number of subjects: 13842
Study 16136031 — intervention group
Group type: COMPARATOR
Intervention: Negative cytological preparations with positive HPV test
Number of subjects: 13842
Study 16136031 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV viral load analysis
Number of subjects: 13842
Study 14560186 — intervention group
Group type: EXPERIMENTAL
Intervention: SB Charitè artificial disc replacement
Number of subjects: 60
Study 14560186 — intervention group
Group type: COMPARATOR
Intervention: BAK anterior interbody fusion
Number of subjects: 60
Study 10098815 — intervention group
Group type: EXPERIMENTAL
Intervention: Head movement strategy (encouraged to move head)
Number of subjects: 14
Study 10098815 — intervention group
Group type: COMPARATOR
Intervention: Hand-control strategy (head kept still)
Number of subjects: 14
Study 8729308 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1.5 mg.kg‐1
Number of subjects: 22
Study 8729308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg.kg‐1
Number of subjects: 22
Study 2069272 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 3 gr/day
Number of subjects: 35
Study 2069272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 2069272 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 2 gr/day
Number of subjects: 35
Study 2069272 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 4 gr/day
Number of subjects: 35
Study 7039663 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete bed rest
Number of subjects: 40
Study 7039663 — intervention group
Group type: COMPARATOR
Intervention: Ambulation as desired
Number of subjects: 40
Study 30659292 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant treatment for 6 months (n=62)
Number of subjects: 90
Study 30659292 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n=28)
Number of subjects: 90
Study 30659292 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant treatment (n=62)
Number of subjects: 90
Study 29402680 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 179
Study 29402680 — intervention group
Group type: COMPARATOR
Intervention: No methadone treatment
Number of subjects: 179
Study 27000465 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA + dexamethasone
Number of subjects: 3280
Study 27000465 — intervention group
Group type: COMPARATOR
Intervention: palonosetron + dexamethasone
Number of subjects: 3280
Study 27000465 — intervention group
Group type: COMPARATOR
Intervention: aprepitant + ondansetron/palonosetron + dexamethasone
Number of subjects: 3280
Study 25131184 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (T-gel) for 6 months
Number of subjects: 274
Study 25131184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 25131184 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (T-gel)
Number of subjects: 274
Study 22421734 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES) applied to the quadriceps, tibialis anterior, and gastrocnemius muscles for 60 minutes per day.
Number of subjects: 0
Study 22421734 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (control) applied to the quadriceps, tibialis anterior, and gastrocnemius muscles for 60 minutes per day.
Number of subjects: 0
Study 19536563 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 352
Study 19536563 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or best supportive care)
Number of subjects: 352
Study 17461702 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g twice/day
Number of subjects: 36
Study 17461702 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 4 g/day
Number of subjects: 36
Study 17461702 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined acetaminophen groups
Number of subjects: 36
Study 17461702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15114096 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasosol (VSL) machine perfusion solution
Number of subjects: 162
Study 15114096 — intervention group
Group type: COMPARATOR
Intervention: Control solution (Belzer MPS)
Number of subjects: 162
Study 17257280 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide, 100 mg at bedtime
Number of subjects: 26
Study 17257280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 10642460 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace-based lifestyle intervention (Workscreen)
Number of subjects: 1206
Study 10642460 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 1206
Study 8925642 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfate-bicarbonate mineral water
Number of subjects: 9
Study 8925642 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 9
Study 1377741 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine
Number of subjects: 866
Study 1377741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 866
Study 1377741 — intervention group
Group type: EXPERIMENTAL
Intervention: Open treatment phase
Number of subjects: 866
Study 6365417 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 19
Study 6365417 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine
Number of subjects: 19
Study 6365417 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 19
Study 31466305 — intervention group
Group type: EXPERIMENTAL
Intervention: Maple products (6% CHO solution)
Number of subjects: 85
Study 31466305 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial sports drink (6% CHO solution)
Number of subjects: 85
Study 31466305 — intervention group
Group type: COMPARATOR
Intervention: Glucose (control CHO solution)
Number of subjects: 85
Study 31466305 — intervention group
Group type: COMPARATOR
Intervention: Water (control solution)
Number of subjects: 85
Study 29947247 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (n=63)
Number of subjects: 148
Study 29947247 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=85)
Number of subjects: 148
Study 25619125 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 274
Study 25619125 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 274
Study 25619125 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) with lowest PAO quartiles
Number of subjects: 274
Study 24576509 — intervention group
Group type: EXPERIMENTAL
Intervention: LapSim
Number of subjects: 40
Study 24576509 — intervention group
Group type: EXPERIMENTAL
Intervention: Box trainer
Number of subjects: 40
Study 24576509 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 21887548 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic tension-free vaginal tape (TVT)
Number of subjects: 160
Study 21887548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 160
Study 21887548 — intervention group
Group type: EXPERIMENTAL
Intervention: Inside-out transobturator (TVT-O)
Number of subjects: 160
Study 21887548 — intervention group
Group type: COMPARATOR
Intervention: All groups (TVT, TOT, TVT-O)
Number of subjects: 160
Study 20626355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron 4 mg at the end of surgery and 12 mg added to PCA (group O)
Number of subjects: 320
Study 20626355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ramosetron 0.3 mg at the end of surgery and no antiemetics added to PCA (group R1)
Number of subjects: 320
Study 20626355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ramosetron 0.3 mg at the end of surgery and 0.6 mg added to PCA (group R2)
Number of subjects: 320
Study 20626355 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antiemetics (group P)
Number of subjects: 320
Study 17717627 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 g of mixed cruciferous vegetables
Number of subjects: 6
Study 17717627 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 g of mixed cruciferous vegetables
Number of subjects: 6
Study 16310607 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous unfractionated heparin for routine thromboprophylaxis
Number of subjects: 22
Study 16310607 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin for specific high-risk patients
Number of subjects: 22
Study 12037271 — intervention group
Group type: EXPERIMENTAL
Intervention: Act‐Hib in combination with BE DTwP (Group A, n = 160)
Number of subjects: 378
Study 12037271 — intervention group
Group type: EXPERIMENTAL
Intervention: TetrAct‐Hib (Group B, n = 160)
Number of subjects: 378
Study 12037271 — intervention group
Group type: EXPERIMENTAL
Intervention: BE DTwP and Act‐Hib as separate injections (Group C, n = 58)
Number of subjects: 378
Study 9873862 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU of alpha interferon thrice weekly (TIW) for 3 months
Number of subjects: 49
Study 9873862 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dose regimen tapering interferon dose from 3 or 6 MU by one-third every 2 months if transaminases were persistently normal
Number of subjects: 49
Study 9873862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose regimen (3 or 6 MU thrice weekly)
Number of subjects: 49
Study 9873862 — intervention group
Group type: COMPARATOR
Intervention: No treatment (biochemical nonresponders followed for an additional 6 months)
Number of subjects: 49
Study 7884542 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein diet
Number of subjects: 12
Study 7884542 — intervention group
Group type: COMPARATOR
Intervention: Animal protein diet
Number of subjects: 12
Study 7884542 — intervention group
Group type: EXPERIMENTAL
Intervention: 18O-cholesterol
Number of subjects: 12
Study 7884542 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C5-cholesterol
Number of subjects: 12
Study 31789476 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI+5-FU/LV
Number of subjects: 69
Study 31789476 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 69
Study 31789476 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI monotherapy
Number of subjects: 69
Study 31578954 — intervention group
Group type: EXPERIMENTAL
Intervention: elvitegravir (150 mg), cobicistat (150 mg), emtricitabine (200 mg), and tenofovir alafenamide (10 mg) daily
Number of subjects: 167
Study 31578954 — intervention group
Group type: COMPARATOR
Intervention: tenofovir disoproxil fumarate (300 mg)
Number of subjects: 167
Study 28960482 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (iron chelator plus amlodipine)
Number of subjects: 56
Study 28960482 — intervention group
Group type: COMPARATOR
Intervention: Control group (iron chelator)
Number of subjects: 56
Study 28960482 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 25362980 — intervention group
Group type: EXPERIMENTAL
Intervention: Tightened tourniquet
Number of subjects: 40
Study 25362980 — intervention group
Group type: COMPARATOR
Intervention: Loosen tourniquet
Number of subjects: 40
Study 25362980 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 23698590 — intervention group
Group type: EXPERIMENTAL
Intervention: +276T-allele carriers
Number of subjects: 168
Study 23698590 — intervention group
Group type: EXPERIMENTAL
Intervention: +45T>G SNP, GG subjects
Number of subjects: 168
Study 21828392 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine invasive strategy (Group A) - early coronary angiography within 48 hours with intended revascularization
Number of subjects: 60
Study 21828392 — intervention group
Group type: COMPARATOR
Intervention: Ischemia-guided strategy (Group B) - catheterization based on myocardial ischemia and viability
Number of subjects: 60
Study 21828392 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine invasive strategy (Group A)
Number of subjects: 60
Study 21828392 — intervention group
Group type: COMPARATOR
Intervention: Ischemia-guided strategy (Group B)
Number of subjects: 60
Study 19634823 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation plate fixation with or without autogenous cancellous bone graft
Number of subjects: 38
Study 16702888 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/d or more (n = 120)
Number of subjects: 235
Study 16702888 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 3 mg/d or more (n = 115)
Number of subjects: 235
Study 15380399 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 15380399 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine plus sustained clonazepam
Number of subjects: 0
Study 15380399 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine plus brief clonazepam
Number of subjects: 0
Study 15380399 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11761130 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Metronome training (15 hours)
Number of subjects: 56
Study 11761130 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 56
Study 11761130 — intervention group
Group type: COMPARATOR
Intervention: Computer video games training (Control group)
Number of subjects: 56
Study 11761130 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Metronome training
Number of subjects: 56
Study 8985298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 25 mg daily
Number of subjects: 42
Study 8985298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily
Number of subjects: 42
Study 8985298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 300 mg daily
Number of subjects: 42
Study 8985298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 8107547 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (100 mg.d-1)
Number of subjects: 20
Study 2959883 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 9
Study 2959883 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol + Ipratropium Bromide
Number of subjects: 9
Study 29582150 — intervention group
Group type: EXPERIMENTAL
Intervention: Artifact-corrected neurofeedback (AC NF)
Number of subjects: 14
Study 29582150 — intervention group
Group type: COMPARATOR
Intervention: Non-artifact-corrected neurofeedback (NAC NF)
Number of subjects: 14
Study 27526120 — intervention group
Group type: EXPERIMENTAL
Intervention: MP4CO (15 mg/kg/dose to 172 mg/kg/dose, single IV doses; two cohorts received fractionated doses of 172 or 344 mg/kg)
Number of subjects: 24
Study 27526120 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 24
Study 27526120 — intervention group
Group type: EXPERIMENTAL
Intervention: MP4CO
Number of subjects: 24
Study 27526120 — intervention group
Group type: EXPERIMENTAL
Intervention: MP4CO and NS
Number of subjects: 24
Study 23974954 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 508